Premium
Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome
Author(s) -
Shah Niketa,
AlAhmari Ali,
AlYamani Arwa,
Dupuis Lee,
Stephens Derek,
Hitzler Johann
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21737
Subject(s) - medicine , mucositis , adverse effect , methotrexate , chemotherapy , toxicity , incidence (geometry) , acute lymphocytic leukemia , pediatrics , leukemia , lymphoblastic leukemia , physics , optics
Background Acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS) presents with an increased incidence, higher frequency of adverse effects and inferior probability of survival. Attempts at improving outcomes face the dilemma posed by the need to avoid excessive toxicity while maintaining the efficacy of treatment. Dose reductions and avoidance of infusions of intermediate and high‐dose methotrexate are common in this group. Procedure In a matched pair analysis we compared adverse effects and survival after ALL chemotherapy using intermediate and high doses of methotrexate in children with and without Down syndrome. Results Following intermediate and high doses of methotrexate to treat primary ALL, children with DS did not require opiate analgesia and parenteral nutrition for severe mucositis more often than children without DS. Children with DS spent more days in hospital and missed more doses of maintenance chemotherapy. Chemotherapy dose reductions were common and in this study had no detectable adverse impact. Event‐free and overall survival (OS) of children with ALL was lower in the DS than the non‐Down syndrome (NDS) control group. The difference, however, was no longer significant during the recent treatment era. Conclusions The feasibility of all treatment elements that are efficacious in pediatric ALL needs to be carefully considered in children with DS. In addition to survival data, the prospective collection of data on both adverse events and treatment modifications is essential to strike a balance between the avoidance of adverse effects and the need for intensive therapy that will safely improve ALL outcomes in this group. Pediatr Blood Cancer 2009;52:14–19. © 2008 Wiley‐Liss, Inc.